Ask Finn← Discover
HEALTH & WELLNESS

Scientists Find a Hidden Way Muscles Control Blood Sugar Without Insulin

By Sydney Parker · Saturday, November 21, 2026
Finn's Take· TL;DR
  • Researchers discovered insulin-independent glucose uptake pathway in muscle called mSGLT, potentially bypassing broken insulin signaling in diabetes patients.
  • Muscle contractions activate mSGLT to import glucose at rates 100x higher than insulin-stimulated uptake, preserved even in insulin-resistant muscles.
  • Early-stage findings in mouse models could lead to new diabetes drugs targeting this pathway, comparable to existing SGLT2 inhibitors.
See this from any side — with sources:
Left takeNeutralRight take

A Hidden Mechanism in Your Muscles

Researchers at the University of Cincinnati have identified an insulin-independent pathway for glucose uptake in skeletal muscle — a finding that could fundamentally change how scientists think about blood sugar control. For the hundreds of millions of people living with diabetes or insulin resistance worldwide, this discovery points toward a treatment frontier that doesn't depend on the body's ability to produce or respond to insulin at all.

Skeletal muscles account for about 40% of human body mass and play a critical role in regulating glucose levels. After a meal, insulin stimulates muscles to absorb and store up to 90% of consumed glucose through a transport protein called GLUT4. In type 2 diabetes, that signal weakens, and glucose builds up in the blood. The newly identified pathway bypasses this broken chain of command entirely.

What the Research Revealed

Working muscle can absorb glucose at rates up to 100 times higher than after a meal, without needing insulin — but scientists had not fully explained how. How muscles accomplish this has remained a mystery despite decades of research. The University of Cincinnati team set out to crack it.

To identify the pathway — which they call mSGLT — UC researchers first had to develop a way to measure glucose uptake in muscle tissue without insulin. Using glucose derivatives transported by SGLT-type transporters but not by GLUT4 proteins, they tested isolated muscles from animal models and electrically stimulated contractions to mimic working muscle. The contracting mouse muscle imported glucose through this insulin-independent route, which shuts down when the sodium pump Na,K-ATPase-α2 is blocked.

In addition to exercise, mSGLT imports glucose under other conditions of adrenergic stimulation, which inhibits pancreatic insulin release and reduces the insulin sensitivity of muscle. That makes the pathway potentially relevant not just during physical activity, but in a range of metabolic scenarios where insulin falls short.

Why This Could Matter for Diabetes Treatment

The findings were published in the Nature Portfolio journal Communications Biology and could open the door to new treatments for diabetes, hyperglycemia, and insulin resistance that directly target this pathway in muscle tissue. The lead researcher drew a striking comparison to existing drugs already on the market.

"A therapy that targets glucose uptake by skeletal muscles could be as impactful as SGLT2 inhibitors that lower blood sugar by stimulating the kidneys to excrete excess glucose in the urine," said Natalie Norman, PhD, the study's first author. SGLT2 inhibitors — drugs like Jardiance — are already among the most widely prescribed diabetes medications in the world, making that comparison significant.

This new discovery is especially relevant for people with insulin resistance or diabetes, whose muscles respond less effectively to insulin and clear glucose more slowly. Working skeletal muscles take up glucose at dramatically greater rates than postprandial insulin-stimulated glucose uptake — and, notably, this remarkable ability is preserved in diabetes, even when muscles become resistant to insulin.

What Comes Next

The study was done in isolated mouse muscle, not in people. The protein and gene responsible have not yet been identified, and no treatment based on the finding currently exists. Scientists are careful to frame this as an early but meaningful step, not a cure on the horizon.

UC researchers will now work to identify the specific protein responsible for mSGLT glucose uptake and determine whether targeting the pathway can improve blood sugar regulation. The mSGLT pathway and its regulation offer potential muscle-specific therapeutic targets for treating hyperglycemia and other conditions when insulin-stimulated glucose disposal into muscle is impaired. If that work succeeds in human models, it could mark the beginning of an entirely new class of diabetes therapies — ones that work with the body's own muscles rather than around a failing hormonal system.

Have a question about this story?
Ask Finn — answers grounded in this article, from any viewpoint.